Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

“Areas with lower vaccination rates, colder weather and higher population density are seeing higher infection rates,” said Dr ...

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

“My son’s lips, at this point, started to turn blue. He also had a febrile seizure, which is why his body was stiff and ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

While no deaths have been reported, hospitals are seeing an influx of patients, particularly children under two with RSV and older adults with the flu. Doctors urge the public to get vaccinated for ...

29 to Oct. 5, when no RSV cases were reported ... according to the Centers for Disease Control and Prevention. Children under 2 and adults over 65 are at particular risk, Patel said.